Lotrafiban is a small molecule inhibitor that targets the glycoprotein IIb/IIIa receptor on platelets, which plays a critical role in blood clot formation. It is primarily used in the development and research of antiplatelet therapies aimed at preventing thrombotic events. Its application lies in the potential treatment of cardiovascular conditions such as acute coronary syndrome and during percutaneous coronary interventions (PCI), where preventing platelet aggregation is crucial. By blocking fibrinogen binding to platelets, Lotrafiban helps reduce the risk of arterial thrombosis. Although it has been studied in clinical trials, its use remains limited due to the emergence of more effective or safer antiplatelet agents. It continues to serve as a valuable tool in understanding platelet biology and drug development for cardiovascular diseases.